380221-63-6

UK-432097 is a highly potent and selective A2AAR agonist with a pKi of 8.4 for human A2AAR. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research[1][2][3].

UK-432097 is a selective adenosine receptor A2AAR full agonist with EC50 of 0.66 ± 0.19 nM. It was recently used to map the structure of the active state of the adenosine A2A receptor.

[1] Fei Xu, et al. Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7. DOI:10.1126/science.1202793
[2] Kenneth A Jacobson, et al. Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Front Cell Neurosci. 2019 Mar 28;13:124. DOI:10.3389/fncel.2019.00124
[3] J Daniel Hothersall, et al. Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics. Mol Pharmacol. 2017 Jan;91(1):25-38. DOI:10.1124/mol.116.105551